NCT06726785View on ClinicalTrials.gov

Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

February 27, 2026

Conditions

Restless Leg Syndrome (RLS)

Trial Locations (1)

94109

RECRUITING

Alethios Inc, San Francisco

All Listed Sponsors

lead

HBC Immunology Inc

INDUSTRY

NCT06726785 - Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment | Biotech Hunter | Biotech Hunter